Efficacy of paclitaxel, carboplatin, and bevacizumab for cervical cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of paclitaxel, carboplatin, and bevacizumab for cervical cancer

Published:2020-06-12 Issue:24 Volume:99 Page:e20558
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Zhang Li,Zheng Chun-yan,Cao Jin-hui,Luo Shu-ling

Funder

Shaanxi Key R&D Program

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference21 articles.

1. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review;Shrestha;Asian Pac J Cancer Prev,2018

2. Cervical Cancer Screening;Sawaya;Med Clin North Am,2017

3. Epidemiology and early detection of cervical cancer;Hillemanns;Oncol Res Treat,2016

4. Cervical cancer: screening, diagnosis and staging;Tsikouras;J BUON,2016

5. Cost-effectiveness analysis of cervical cancer screening strategies in urban China;Peng;Zhonghua Zhong Liu Za Zhi,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated Network Pharmacology and Metabolomics to Dissect the Mechanisms of Naringin for Treating Cervical Cancer;Combinatorial Chemistry & High Throughput Screening;2024-03

2. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer;International Journal of Gynecologic Cancer;2022-01-27

3. Efficacy of cisplatin plus paclitaxel as chemotherapy in patients with cervical cancer after laparoscopic nerve-sparing extensive hysterectomy and its effect on immune function;PAK J PHARM SCI;2022

4. Synthesis and Anti-cancer Activity of Paclitaxel−Coumarin Conjugate;Current Organic Synthesis;2021-09

5. Current treatment modalities in major gynecologic cancers: Emphasis on response rates;Overcoming Drug Resistance in Gynecologic Cancers;2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3